Quantifying the return of headache in triptan-treated migraineurs: An observational study

Cephalalgia

Volumn 30, Issue 7, 2010, Pages 838-846

  Sheftell, Fred ^a,b   Almas, Mary ^c   Weeks, Randall ^d   Mathew, Ninan T ^e   Pitman, Verne ^c   Lipton, Richard B ^b,f  

^a NEW ENGLAND CENTER FOR HEADACHE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c PFIZER INC   (United States)

^d New England Institute for Behavioral Medicine   (United States)

^e Houston Headache Clinic   (United States)

^f MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

headache return; migraine; observational study; triptan

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN; TRYPTAMINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MIGRAINE; OBSERVATIONAL STUDY; PAIN; PATIENT ASSESSMENT; PRESCHOOL CHILD; SCHOOL CHILD; TREATMENT FAILURE; TREATMENT RESPONSE; CLINICAL TRIAL; MEDICAL RECORD; MULTICENTER STUDY; PATIENT SATISFACTION; RECURRENT DISEASE;

ADULT; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIGRAINE DISORDERS; PATIENT SATISFACTION; RECURRENCE; TRYPTAMINES;

EID: 78349253100     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102409354390     Document Type: Article

References (22)

1. Matchar DB, Young WB, Rosenberg JH Evidence-based guidelines for migraine headache in the primary care settings: pharmacological management of acute attacks. American Academy of Neurology. http://www.aan.com/professionals/ practice/pdfs/gl0087.pdf ( 2000, accessed September 2009 ).
2. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001 ; 358: 1668-1675.
3. Pascual J., Mateos V., Roig C., Sanchez-Del-Rio M., Jimenez D. Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability. Headache 2007 ; 47: 1152-1168.
4. Lipton RB, Stewart WF Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999 ; 39: S20-25.
5. Goldstein J., Tiseo PJ, Albert KS, Li C., Sykes CR Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Headache 2006 ; 46: 1142-1150.
6. Sheftell FD, Feleppa M., Tepper S., Volcy M., Rapoport AM, Bigal ME Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache 2004 ; 44: 661-668.
7. Visser WH, de Vriend RH, Jaspers MW, Ferrari MD Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 1996 ; 47: 46-51.
8. Dodick DW, Lipsy RJ Advances in migraine management: implications for managed care organizations. Manag Care 2004 ; 13: 45-51.
9. Dodick DW, Lipton RB, Goadsby PJ, et al. Predictors of migraine headache recurrence: a pooled analysis from the eletriptan database. Headache 2008 ; 48: 184-193.
10. Sheftell F., O'Quinn S., Watson C., Pait D., Winter P. Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. Headache 2000 ; 40: 103-110.
11. Aurora SK Headache recurrence as a criterion for assessing efficacy of triptans: a perspective. Headache 2002 ; 42: 70-79.
12. Tfelt-Hansen P., Block G., Dahlf C., et al. Guidelines for controlled trials of drugs in migraine. 2 nd ed. Cephalalgia 2000 ; 20: 765-786.
13. Cady RK, Sheftell F., Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 2000 ; 22: 1035-1048.
14. Pascual J. Clinical benefits of early triptan therapy for migraine. Headache 2002 ; 42 (Suppl 1). 10-17.
15. Dodick DW Applying the benefits of the AwM study in the clinic. Cephalalgia 2008 ; 28 (Suppl 2). 42-49.
16. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. 2 nd ed. Cephalalgia 2004 ; 24 (Suppl 1). 9-160.
17. Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 2001 ; 56 (6 Suppl 1). S20-28.
18. Carpay J., Schoenen J., Ahmad F., Kinrade F., Boswell D. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin Ther 2004 ; 26: 214-223.
19. Sheftell FD, Dahlof CG, Brandes JL, Agosti R., Jones MW, Barrett PS Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/ rapid-release formulation of sumatriptan tablets. Clin Ther 2005 ; 27: 407-417.
20. Winner P., Landy S., Richardson M., Ames M. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. Clin Ther 2005 ; 27: 1785-1794.
21. Lipton RB, Hamelsky SW, Dayno JM What do patients with migraine want from acute migraine treatment? Headache 2002 ; 42: S3-9.
22. Graud G., Keywood C., Senard JM Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003 ; 43: 376-388.